Clinical trials sponsored by Pierre Fabre Medicament

Phase breakdown

Conditions studied

Recruiting trials led by Pierre Fabre Medicament

• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 71 locations
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
  NCT06669117 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
  NCT06043817 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
  NCT06567015 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations

Common questions

How many trials is Pierre Fabre Medicament recruiting for?

Pierre Fabre Medicament is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.